Aphakia, Cataract, Corneal Astigmatism
Conditions
Keywords
Toric, Intraocular lens
Brief summary
The purpose of this study was to evaluate the safety and effectiveness of the HARMONI® Modular Intraocular Lens System with a toric optic (HMTIOL) in subjects with pre-existing corneal astigmatism in need of cataract surgery.
Detailed description
Subjects with visually significant bilateral cataracts (cortical, nuclear, posterior subcapsular, or a combination) were implanted unilaterally (in one eye only) or bilaterally (in both eyes) with the HMTIOL. A total of 7 study visits were planned, including a preoperative visit, operative visits for each eye, and 4 follow-up visits at 1 day, 1 week, 1 month, and 3 months postoperative. The total duration of participation for each subject was up to 6 months, including the preoperative period (up to 3 months). Alcon Research, LLC, acquired ClarVista Medical in 2017. This study was designed and conducted by ClarVista Medical, Inc. The study results were collected, analyzed, and provided by ClarVista Medical, Inc. to Alcon Research, LLC.
Interventions
DEVICEHARMONI® Modular Toric Intraocular Lens
Two-component system consisting of a base and a separate toric optic
PROCEDURECataract extraction with intraocular lens (IOL) implantation
Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
Sponsors
ClarVista Medical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Planned removal of visually significant bilateral cataract by manual phacoemulsification cataract extraction * Pre-existing corneal astigmatism in at least 1 eye of 0.75 to 2.50 diopter (D) * Target dioptric lens power within the range of 16 - 26 D * Willing to discontinue contact lens wear for the duration of the study * BCVA projected to be ≤0.2 logarithm minimum angle of resolution (LogMAR) * Stable cornea * Dilated pupil size at least 7.0 millimeters (mm) * Able to understand and provide informed consent. Key
Exclusion criteria
* History of any intraocular or corneal surgery in study eye (including refractive) * Pregnant or lactating * History of any clinically significant retinal pathology or ocular diagnosis in study eye that could alter or limit final postoperative visual prognosis * History of ocular conditions which could affect the stability of the IOL in study eye * Any anterior segment pathology likely to increase the risk of complications from phacoemulsification cataract extraction in study eye * Any visually significant intraocular media opacity other than cataract in study eye * Uncontrolled glaucoma in study eye * Uncontrolled systemic disease * Severe dry eye that would impair the ability to obtain reliable study measurements * Systemic medication that may confound the outcome or increase the intraoperative and postoperative risk to the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Manifest Refraction Cylinder (MRCYL) for Eyes Implanted With HMTIOL | Month 1 postoperative, Month 3 postoperative | A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of added correction needed to compensate for any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number, with a less negative number indicating a lesser amount of added correction. No formal statistical hypothesis testing was planned. |
| Mean Manifest Refraction Cylinder (MRCYL) Prediction Error (PE) for Eyes Implanted With HMTIOL | Month 1 postoperative, Month 3 postoperative | A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. MRCYL PE was calculated as postoperative MRCYL adjusted to 6 meters minus MRCYL target residual refractive error (TRRE), with a lower absolute value indicating a more accurate cylinder power calculation. No formal statistical hypothesis testing was planned. |
| MRCYL PE for Eyes Implanted With HMTIOL Per Vector Analyses | Month 1 postoperative, Month 3 postoperative | Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL PE is calculated as postoperative MRCYL adjusted to 6 meters minus MRCYL target residual refractive error (TRRE), with a lower absolute value indicating a more accurate cylinder power calculation. No formal statistical hypothesis testing was planned. |
| Mean Reduction in Cylinder Power for Eyes Implanted With HMTIOL | Baseline (Day 0 preoperative), Month 3 postoperative | A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. No formal statistical hypothesis testing was planned. |
| Mean Percent Reduction in Cylinder Power for Eyes Implanted With HMTIOL | Baseline (Day 0 preoperative), Month 3 postoperative | A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. Therefore, the cylindrical power percent reduction was the cylinder power reduction divided by the absolute value of preoperative magnitude of corneal cylinder (K) × 100. A higher number (greater percent reduction) indicates better astigmatism correction by the toric IOL. No formal statistical hypothesis testing was planned. |
| Mean Manifest Refraction Spherical Equivalent (MRSE) Prediction Error (PE) | Month 1 postoperative, Month 3 postoperative | A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. The manifest refraction spherical equivalent (MRSE) was calculated as follows: sphere + 1/2 cylinder, and measured in diopters (D). MRSE PE was calculated as postoperative MRSE adjusted to 6 meters minus MRSE target residual refractive error (TRRE). The lower the absolute number, the more accurate the IOL power calculation is. No formal statistical hypothesis testing was planned. |
| Mean Absolute Misalignment of IOL Meridian - Target Versus Actual at Operative Visit | Day 0 (operative) | Absolute misalignment of IOL meridian was defined as the summation of IOL misplacement and IOL rotation. A lower number indicates minimal IOL misalignment. No formal statistical hypothesis testing was planned. |
| Mean Absolute Rotation of IOL Meridian by Visit | Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative | IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees. No formal statistical hypothesis testing was planned. |
| Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative | IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees and is reported categorically. No formal statistical hypothesis testing was planned. |
| Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | Baseline (Day 0 preoperative), Week 1 postoperative, Month 1 postoperative, Month 3 postoperative | Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with the correction obtained from manifest refraction testing. BCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned. |
| Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative | Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with an optical infinity adjustment of +0.25 diopter (D). UCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned. |
| Standard Error of the Mean in Lens Power A-constant for Refinement | Day 0 operative | The A-constant (lens power constant) is a theoretical value that is used to calculate the power of the intraocular lens. It relates the lens power to the eye's axial length and keratometry. It is not expressed in units; it is specific to the design of the IOL and its intended location and orientation within the eye. A-constants are typically empirically developed for new IOLs based on hundreds of clinical uses. Data from a sufficient number of eyes are needed in order to reduce bias due to surgical technique, unusual eyes, and differences in equipment, such that the standard error of the mean in the lens power constant would be less than ±0.10 mm (approximately ±0.2 diopter). This study represented the first clinical use of the HMTIOL. |
| Number of Ocular Adverse Events Through Month 3 | Up to Month 3 postoperative | Ocular adverse events were identified as outlined in ISO 11979-2014 Annex B. No formal statistical hypothesis testing was planned. |
| Number of Device-Related Secondary Surgical Interventions (SSI) Other Than Optic Exchange and Rotational Adjustment of the HMTIOL | Up to Month 3 postoperative | A secondary surgical intervention (SSI) was defined as a surgical procedure that occurred after primary implantation and was conducted for the purpose of resolving residual refractive error (RRE) and optimizing visual outcomes. No formal statistical hypothesis testing was planned. |
| Number of Device Deficiencies Post Implantation | Up to Month 3 postoperative | A device deficiency was defined as a failure of the device to meet its performance specifications or expectations, or otherwise not perform as intended. This could include either a malfunction or damage to the device or any part thereof, regardless of the source of malfunction or damage, including user error, and regardless of the presence of injury (or lack thereof) to subject, user, or bystander. No formal statistical hypothesis testing was planned. |
| Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Month 1 postoperative, Month 3 postoperative | Preservation of BCDVA was defined in terms of lines lost when reading the ETDRS chart at each visit compared to the prior best-achieved BCDVA. Loss of \< 1 line included subjects with less than a 1 line loss, no change or improvement in BCDVA. No formal statistical hypothesis testing was planned. |
Countries
New Zealand
Participant flow
Recruitment details
Subjects were recruited from one investigative site located in New Zealand.
Pre-assignment details
Of the 16 subjects (25 eyes) enrolled in the study, 4 subjects (7 eyes) were exited prior to implantation as screen failures, and 1 eye in 1 subject was exited prior to implantation due to a medical condition. This reporting group includes all implanted subjects (12) and eyes (17).
Participants by arm
| Arm | Count |
|---|---|
| HMTIOL HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | HMTIOL |
|---|---|
| Age, Continuous | 69.7 years STANDARD_DEVIATION 11.7 |
| Race/Ethnicity, Customized Asian | 0 Participants |
| Race/Ethnicity, Customized Black | 0 Participants |
| Race/Ethnicity, Customized Caucasian | 10 Participants |
| Race/Ethnicity, Customized Other | 2 Participants |
| Region of Enrollment New Zealand | 12 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 17 |
| other Total, other adverse events | 0 / 12 | 2 / 17 |
| serious Total, serious adverse events | 0 / 12 | 0 / 17 |
Outcome results
Primary
Mean Absolute Misalignment of IOL Meridian - Target Versus Actual at Operative Visit
Absolute misalignment of IOL meridian was defined as the summation of IOL misplacement and IOL rotation. A lower number indicates minimal IOL misalignment. No formal statistical hypothesis testing was planned.
Time frame: Day 0 (operative)
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HMTIOL | Mean Absolute Misalignment of IOL Meridian - Target Versus Actual at Operative Visit | 2.6 degrees | Standard Deviation 1.7 |
Primary
Mean Absolute Rotation of IOL Meridian by Visit
IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| HMTIOL | Mean Absolute Rotation of IOL Meridian by Visit | Rotation from operative to Day 1 postoperative | 1.9 degrees | Standard Deviation 1.8 |
| HMTIOL | Mean Absolute Rotation of IOL Meridian by Visit | Rotation from operative to Week 1 postoperative | 2.3 degrees | Standard Deviation 1.6 |
| HMTIOL | Mean Absolute Rotation of IOL Meridian by Visit | Rotation from operative to Month 1 postoperative | 2.9 degrees | Standard Deviation 2.2 |
| HMTIOL | Mean Absolute Rotation of IOL Meridian by Visit | Rotation from operative to Month 3 postoperative | 2.4 degrees | Standard Deviation 2.3 |
Primary
Mean Manifest Refraction Cylinder (MRCYL) for Eyes Implanted With HMTIOL
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of added correction needed to compensate for any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number, with a less negative number indicating a lesser amount of added correction. No formal statistical hypothesis testing was planned.
Time frame: Month 1 postoperative, Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| HMTIOL | Mean Manifest Refraction Cylinder (MRCYL) for Eyes Implanted With HMTIOL | Month 1 postoperative | -0.50 diopter | Standard Deviation 0.95 |
| HMTIOL | Mean Manifest Refraction Cylinder (MRCYL) for Eyes Implanted With HMTIOL | Month 3 postoperative | -0.57 diopter | Standard Deviation 0.98 |
Primary
Mean Manifest Refraction Cylinder (MRCYL) Prediction Error (PE) for Eyes Implanted With HMTIOL
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. MRCYL PE was calculated as postoperative MRCYL adjusted to 6 meters minus MRCYL target residual refractive error (TRRE), with a lower absolute value indicating a more accurate cylinder power calculation. No formal statistical hypothesis testing was planned.
Time frame: Month 1 postoperative, Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| HMTIOL | Mean Manifest Refraction Cylinder (MRCYL) Prediction Error (PE) for Eyes Implanted With HMTIOL | Month 1 postoperative | 0.01 diopter | Standard Deviation 0.26 |
| HMTIOL | Mean Manifest Refraction Cylinder (MRCYL) Prediction Error (PE) for Eyes Implanted With HMTIOL | Month 3 postoperative | -0.03 diopter | Standard Deviation 0.29 |
Primary
Mean Manifest Refraction Spherical Equivalent (MRSE) Prediction Error (PE)
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. The manifest refraction spherical equivalent (MRSE) was calculated as follows: sphere + 1/2 cylinder, and measured in diopters (D). MRSE PE was calculated as postoperative MRSE adjusted to 6 meters minus MRSE target residual refractive error (TRRE). The lower the absolute number, the more accurate the IOL power calculation is. No formal statistical hypothesis testing was planned.
Time frame: Month 1 postoperative, Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| HMTIOL | Mean Manifest Refraction Spherical Equivalent (MRSE) Prediction Error (PE) | Month 1 postoperative | 0.14 diopter | Standard Deviation 0.41 |
| HMTIOL | Mean Manifest Refraction Spherical Equivalent (MRSE) Prediction Error (PE) | Month 3 postoperative | 0.26 diopter | Standard Deviation 0.43 |
Primary
Mean Percent Reduction in Cylinder Power for Eyes Implanted With HMTIOL
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. Therefore, the cylindrical power percent reduction was the cylinder power reduction divided by the absolute value of preoperative magnitude of corneal cylinder (K) × 100. A higher number (greater percent reduction) indicates better astigmatism correction by the toric IOL. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 preoperative), Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HMTIOL | Mean Percent Reduction in Cylinder Power for Eyes Implanted With HMTIOL | 76.2 percent reduction | Standard Deviation 27.4 |
Primary
Mean Reduction in Cylinder Power for Eyes Implanted With HMTIOL
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 preoperative), Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HMTIOL | Mean Reduction in Cylinder Power for Eyes Implanted With HMTIOL | 1.15 diopter | Standard Deviation 0.63 |
Primary
MRCYL PE for Eyes Implanted With HMTIOL Per Vector Analyses
Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL PE is calculated as postoperative MRCYL adjusted to 6 meters minus MRCYL target residual refractive error (TRRE), with a lower absolute value indicating a more accurate cylinder power calculation. No formal statistical hypothesis testing was planned.
Time frame: Month 1 postoperative, Month 3 postoperative
Population: Vector analyses (Eydelman 2006) based on the cylinder power and axis were planned but were not performed.
Primary
Number of Device Deficiencies Post Implantation
A device deficiency was defined as a failure of the device to meet its performance specifications or expectations, or otherwise not perform as intended. This could include either a malfunction or damage to the device or any part thereof, regardless of the source of malfunction or damage, including user error, and regardless of the presence of injury (or lack thereof) to subject, user, or bystander. No formal statistical hypothesis testing was planned.
Time frame: Up to Month 3 postoperative
Population: Safety Analysis: All eyes with attempted study lens implantation (successful or aborted after contact with the eye)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HMTIOL | Number of Device Deficiencies Post Implantation | 0 device deficiency |
Primary
Number of Device-Related Secondary Surgical Interventions (SSI) Other Than Optic Exchange and Rotational Adjustment of the HMTIOL
A secondary surgical intervention (SSI) was defined as a surgical procedure that occurred after primary implantation and was conducted for the purpose of resolving residual refractive error (RRE) and optimizing visual outcomes. No formal statistical hypothesis testing was planned.
Time frame: Up to Month 3 postoperative
Population: Safety Analysis: All eyes with attempted study lens implantation (successful or aborted after contact with the eye)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HMTIOL | Number of Device-Related Secondary Surgical Interventions (SSI) Other Than Optic Exchange and Rotational Adjustment of the HMTIOL | 1 SSI |
Primary
Number of Eyes With Absolute Rotation of IOL Meridian by Visit
IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees and is reported categorically. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit. Analysis of IOL rotation was planned for rotation categories of ≤ 5°, \< 10°, \< 20°, and \< 30°. Instead, IOL rotation was reported for categories of ≤ 5°, \> 5° to ≤ 10°, \> 10° to ≤ 20°, and \> 20°.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HMTIOL | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 20 degrees | 0 eyes |
| HMTIOL | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative ≤ 5 degrees | 12 eyes |
| HMTIOL | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 5 to ≤ 10 degrees | 1 eyes |
| HMTIOL | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 10 to ≤ 20 degrees | 0 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 20 degrees | 0 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 10 to ≤ 20 degrees | 0 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 5 to ≤ 10 degrees | 1 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative ≤ 5 degrees | 12 eyes |
| HMTIOL - Month 1 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative ≤ 5 degrees | 12 eyes |
| HMTIOL - Month 1 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 5 to ≤ 10 degrees | 1 eyes |
| HMTIOL - Month 1 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 10 to ≤ 20 degrees | 0 eyes |
| HMTIOL - Month 1 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 20 degrees | 0 eyes |
| HMTIOL - Month 3 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 5 to ≤ 10 degrees | 1 eyes |
| HMTIOL - Month 3 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative ≤ 5 degrees | 12 eyes |
| HMTIOL - Month 3 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 20 degrees | 0 eyes |
| HMTIOL - Month 3 Postoperative | Number of Eyes With Absolute Rotation of IOL Meridian by Visit | Rotation from operative > 10 to ≤ 20 degrees | 0 eyes |
Primary
Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3
Preservation of BCDVA was defined in terms of lines lost when reading the ETDRS chart at each visit compared to the prior best-achieved BCDVA. Loss of \< 1 line included subjects with less than a 1 line loss, no change or improvement in BCDVA. No formal statistical hypothesis testing was planned.
Time frame: Month 1 postoperative, Month 3 postoperative
Population: Safety Analysis: All eyes with attempted study lens implantation (successful or aborted after contact with the eye)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HMTIOL | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss >= 1 line | 1 eyes |
| HMTIOL | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss >= 3 lines | 0 eyes |
| HMTIOL | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss >= 2 lines | 0 eyes |
| HMTIOL | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss >= 4 lines | 0 eyes |
| HMTIOL | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss < 1 line | 16 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss >= 4 lines | 0 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss < 1 line | 16 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss >= 1 line | 1 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss >= 2 lines | 0 eyes |
| HMTIOL - Week 1 Postoperative | Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 | Loss >= 3 lines | 0 eyes |
Primary
Number of Ocular Adverse Events Through Month 3
Ocular adverse events were identified as outlined in ISO 11979-2014 Annex B. No formal statistical hypothesis testing was planned.
Time frame: Up to Month 3 postoperative
Population: Safety Analysis: All eyes with attempted study lens implantation (successful or aborted after contact with the eye)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HMTIOL | Number of Ocular Adverse Events Through Month 3 | Astigmatism | 1 event |
| HMTIOL | Number of Ocular Adverse Events Through Month 3 | Ciliary zonular dehiscence | 1 event |
| HMTIOL | Number of Ocular Adverse Events Through Month 3 | Intraocular injection | 1 event |
| HMTIOL | Number of Ocular Adverse Events Through Month 3 | Macular oedema | 1 event |
| HMTIOL | Number of Ocular Adverse Events Through Month 3 | Vitrectomy | 1 event |
Primary
Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with the correction obtained from manifest refraction testing. BCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 preoperative), Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HMTIOL | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/40 Snellen or Better | 64.7 percentage of eyes |
| HMTIOL | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/25 Snellen or Better | 47.1 percentage of eyes |
| HMTIOL | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | Worse than 20/40 Snellen | 35.3 percentage of eyes |
| HMTIOL | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/32 Snellen or Better | 64.7 percentage of eyes |
| HMTIOL | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/20 Snellen or Better | 35.3 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/32 Snellen or Better | 88.2 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/40 Snellen or Better | 94.1 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | Worse than 20/40 Snellen | 5.9 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/25 Snellen or Better | 88.2 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/20 Snellen or Better | 82.4 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/32 Snellen or Better | 94.1 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/20 Snellen or Better | 82.4 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/25 Snellen or Better | 94.1 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/40 Snellen or Better | 94.1 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | Worse than 20/40 Snellen | 5.9 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/40 Snellen or Better | 100.0 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/25 Snellen or Better | 88.2 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/20 Snellen or Better | 88.2 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | 20/32 Snellen or Better | 100.0 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit | Worse than 20/40 Snellen | 0.0 percentage of eyes |
Primary
Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with an optical infinity adjustment of +0.25 diopter (D). UCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Population: Implanted Eye: All eyes with successful HMTIOL implantation and data at visit
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HMTIOL | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/40 Snellen or Better | 47.1 percentage of eyes |
| HMTIOL | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/20 Snellen or Better | 0.0 percentage of eyes |
| HMTIOL | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | Worse than 20/40 Snellen | 52.9 percentage of eyes |
| HMTIOL | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/25 Snellen or Better | 5.9 percentage of eyes |
| HMTIOL | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/32 Snellen or Better | 35.3 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/40 Snellen or Better | 82.4 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/32 Snellen or Better | 70.6 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/25 Snellen or Better | 35.3 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | Worse than 20/40 Snellen | 17.6 percentage of eyes |
| HMTIOL - Week 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/20 Snellen or Better | 23.5 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/32 Snellen or Better | 76.5 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/20 Snellen or Better | 52.9 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/25 Snellen or Better | 76.5 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/40 Snellen or Better | 88.2 percentage of eyes |
| HMTIOL - Month 1 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | Worse than 20/40 Snellen | 11.8 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | Worse than 20/40 Snellen | 11.8 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/20 Snellen or Better | 47.1 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/40 Snellen or Better | 88.2 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/32 Snellen or Better | 76.5 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/25 Snellen or Better | 70.6 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/32 Snellen or Better | 76.5 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/40 Snellen or Better | 88.2 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/20 Snellen or Better | 52.9 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | Worse than 20/40 Snellen | 11.8 percentage of eyes |
| HMTIOL - Month 3 Postoperative | Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit | 20/25 Snellen or Better | 76.5 percentage of eyes |
Primary
Standard Error of the Mean in Lens Power A-constant for Refinement
The A-constant (lens power constant) is a theoretical value that is used to calculate the power of the intraocular lens. It relates the lens power to the eye's axial length and keratometry. It is not expressed in units; it is specific to the design of the IOL and its intended location and orientation within the eye. A-constants are typically empirically developed for new IOLs based on hundreds of clinical uses. Data from a sufficient number of eyes are needed in order to reduce bias due to surgical technique, unusual eyes, and differences in equipment, such that the standard error of the mean in the lens power constant would be less than ±0.10 mm (approximately ±0.2 diopter). This study represented the first clinical use of the HMTIOL.
Time frame: Day 0 operative
Population: The planned sample size of 200 eyes was calculated based on the planned refinement of the A-Constant; however, due to the change in the study design, a sample size of 30 was targeted and a total of 17 eyes were implanted. Refinement of the A-Constant was planned, but not completed, due to the change in study design. No data was collected.